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’INTRODUCTION
Acriticalneedwithinthebiochemicalandbiomedicalresearch
sector is the identiﬁcation of low-abundance biomarkers that are
predictiveofearly-stagediseaseorthatcorrelatewiththerapeutic
outcomeortoxicity.
1Whiletheinterestinthepotentialandvalue
of biomarkers has never been greater, the research investment in
biomarker discovery and clinical validation has yielded a very
poor return to date.
1,2 This poor return is due in part to the low
abundance of early disease biomarkers that exist at a concentra-
tion below the detection limit of biomarker discovery platforms.
Protein biomarker discovery and quantitation by mass spectro-
metry (MS) and multiple reaction monitoring (MRM) are
powerful approaches
1,2 but are severely limited in their practical
application for complex clinical samples because of their low
eﬀective sensitivity.
3 The analyte detection sensitivity for MS or
MRM applied directly toacomplexbodyﬂuidistypically greater
than 50 ng mL
 1.
4 In contrast, the vast majority of diagnostic
analytes measured in the clinical laboratory by immunoassay
platformsfallintherangebetween50pgmL
 1and10ngmL
 1.
5
Thus, the most important protein biomarkers, particularly
those derived from early-stage disease,
6 are invisible to conven-
tional MS or MRM.
7 MS and MRM lack practical sensitivity
becauseoftechnicalandphysiologicalconstraints.Thevolumeof
sample introduced into the MS is very small (<1 μL) containing
only a small number of target analyte molecules and thereby limiting
the detection sensitivity. In addition, low-abundance, low-
molecular weight proteins and peptides are masked by billion-
fold excess quantities of resident proteins such as immunoglo-
bulin and albumin. The MS input sample is strictly limited in the
maximum total protein (<50 μg) content, a value lower than the
serumorplasmaproteincontentin1μL,thevolumeoftheinput
sample for the mass spectrometer. Consequently, increasing the
sensitivity is not simply a matter of concentrating the sample
becausethiswilloverwhelmthetotalproteincapacityintroduced
into the MS. A further barrier to biomarker discovery is the
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ABSTRACT: Many low-abundance biomarkers for early detection of cancer and other
diseases are invisible to mass spectrometry because they exist in body ﬂuids in very low
concentrations, are masked by high-abundance proteins such as albumin and immunoglo-
bulins, and are very labile. To overcome these barriers, we created porous, buoyant,
core shell hydrogel nanoparticles containing novel high aﬃnity reactive chemical baits for
protein and peptide harvesting, concentration, and preservation in body ﬂuids. Poly(N-
isopropylacrylamide-co-acrylic acid) nanoparticles were functionalized with amino-containing dyes via zero-length cross-linking
amidation reactions.Nanoparticlesfunctionalizedinthecorewith17diﬀerent(12chemicallynovel) molecularbaitsshowed preferential
high aﬃnities(KD<1 0
 11M) for speciﬁclow-abundanceprotein analytes.Apoly(N-isopropylacrylamide-co-vinylsulfonic acid)
shellwasaddedtothecoreparticles.Thisshellchemistryselectivelypreventedunwantedentryofallsizepeptidesderivedfrom
albuminwithouthinderingthepenetrationofnon-albuminsmallproteinsandpeptides.Proteinsandpeptidesenteredthecore
to be captured with high aﬃnity by baits immobilized in the core. Nanoparticles eﬀectively protected interleukin-6 from
enzymatic degradation in sweat and increased the eﬀective detection sensitivity of human growth hormone in human urine
using multiple reaction monitoring analysis. Used in whole blood as a one-step, in-solution preprocessing step, the
nanoparticles greatly enriched the concentration of low-molecular weight proteins and peptides while excluding albumin
andotherproteinsabove30kDa;thisachieveda10,000-foldeﬀectiveampliﬁcationoftheanalyteconcentration,enablingmass
spectrometry (MS) discovery of candidate biomarkers that were previously undetectable.19179 dx.doi.org/10.1021/ja207515j |J. Am. Chem. Soc. 2011, 133, 19178–19188
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lability and perishability of candidate biomarkers ex vivo follow-
ingclinicalsamplecollection.Diagnosticproteinsandpeptidesin
body ﬂuids are subject to rapid enzymatic degradation following
collection.
8 In the present studywe show that modiﬁedhydrogel
nanoparticles can provide a means to overcome all of these
technicalandphysiological barriers andsigniﬁcantlyimprovethe
sensitivity of detection, and the preservation, of candidate bio-
markers in a single step.
Hydrogelnanoparticleshavebeenextensivelydescribedinthe
literature as good candidate materials for drug delivery
9 12 and
in vivo imaging purposes.
13 In contrast to their application as
drug delivery vehicles, we have proposed the use of hydrogel
nanoparticles for sequestering rather than releasing target mole-
cules.
14 19
In this study, open-meshwork core shell hydrogel nanopar-
ticleswerefunctionalizedwithcombinationsofnovelorganicdye
baits. Speciﬁc dye chemistries immobilized in the particle core
possess extremely high aﬃnity for select classes of proteins and
peptides (Figure 1). Unwanted high-molecular weight proteins
such as albumin and immunoglobulins are excluded from enter-
ing the particles because of the restrictive, eﬀective pore size of
the hydrogel that acts as a molecular sieve. Albumin fragments
are also an unwanted contaminant present in the blood.
20 To
further exclude unwanted contaminating albumin fragments
small enough to penetrate the shell, the shell contains a chemical
species (vinylsulfonic acid, VSA) that selectively prevents entry
of albumin-derived peptides of all sizes (Figure 1), without
hindering the capture of non-albumin proteins and peptides
small enough to enter the particle.
Some classes of organic dyes (indocyanine green,
21 Cibacron
Blue F3GA,
22 Coomassie Blue,
23 triarylmethane dyes,
24 eosin
dyes
25) have been used in the past as protein binding agents and
inhibitors of protein protein interactions.
26 Cibacron Blue
F3GA and related dyes are most extensively studied as ligands
in aﬃnity chromatography. A widely accepted mechanism that
has been proposed to explain the high-aﬃnity binding of
Cibacron Blue F3GA and related dyes to proteins is based on
hydrophobic and electrostatic forces.
27 The speciﬁcity of the
dye protein interaction depends mainly on hydrophobic inter-
actions, whereas electrostatic forces contribute to the stability of
interaction.
27 The dye binding site on the surface of the target
protein is a nonpolar pocket surrounded by hydrophilic amino
acid residues.
28 Moreover, the protein binding sites are often
located in areas overlapping with the binding sites of biological
ligands with respect to other parts of the protein surface.
29
Organic reactive dyes can insert aromatic rings into nonpolar
hydrophobic pockets of the protein surface, while the ﬂanking
portions of the dye and protein molecules can rearrange,
depending on energy constraints. Since both active protein sites
and dye molecules have limited conformational freedom, some
speciﬁcity is achieved.
30
Increasing the size of the dye molecule ring system can
enhance the speciﬁcity.
28 For example, Cibacron Blue F3GA
forms a strong bond with speciﬁc classes of enzymes (dehydro-
genases and kinases) because the 1-amino-4-(40-aminopheny-
lamino)-anthraquinone-2,30-disulfonic acid part of the dye ﬁts
welltoastructuralelementoftheenzymecalledthedinucleotide
Figure 1. (A) Schematic representation of core shell hydrogel nano-
particles.(B)Porousnatureofthehydrogelparticleshellhasaneﬀective
pore size that acts as a molecular sieve with a cutoﬀ determined by the
cross-link density. Proteins small enough to enter the particle are
captured by the high-aﬃnity bait. The high aﬃnity permits very rapid
sequestration of target analytes and dissociation from carrier proteins.
The shell contains a chemical species (vinylsulfonic acid, VSA) that
selectively prevents entry of contaminating albumin-derived peptides of
all sizes without hindering the capture of non-albumin proteins and
peptides small enough to enter the particle. (C) Nanoparticles can be
producedinlargequantitieswithuniformsizedistribution(atomicforce
microscopy image).
Figure 2. High-aﬃnity chemical baits covalently incorporated into
hydrogel nanoparticle cores or shells. ABB, DB3, PR1, AB48, DY3,
AB1,DO3,DY9,R12,TBO,PR,andAB2havenotbeenpreviouslyused
for protein aﬃnity chromatography.19180 dx.doi.org/10.1021/ja207515j |J. Am. Chem. Soc. 2011, 133, 19178–19188
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binding fold.
31 In addition to high speciﬁc binding of some
classes of proteins, Cibacron Blue F3GA also forms nonspeciﬁc
complexes with additional proteins. This latter attribute is most
likelyduetotheabilityofthedyetoactasweakcationexchanger
through its sulfonic groups.
28
Most of the bait dyes used in this work have never been used
for aﬃnity chromatography or protein capture in the past and
were foundtohave highaﬃnity forselect classes of proteins (see
Figure 2). In fact it can be hypothesized, on the basis of the
proposed mechanism of binding, that all ionic aromatic com-
pounds, separate from Cibacron Blue F3GA and related dyes,
should be capable of binding all classes of proteins and peptides
that have a suﬃciently large exposed hydrophobic region.
28
Dye-functionalized nanoparticles can be introduced into
whole blood at the time of collection (Figure 3). In one step,
insolution,andinminutes,thenanoparticle(a)aﬃnitiescapture
all the target analytes in the entire ﬂuid phase (plasma), (b) strip
targetanalytesoﬀofthecarrierproteins,(c)protectthecaptured
targetproteinfromdegradation,and(d)excludeallsizeclassesof
albumin-derived peptides. The buoyant, open-meshwork, sphe-
ricalnanoporousparticles(0.5 0.7μmdiam)remainasacolloid
in suspension in the ﬂuid phase and are in open exchange with
the surrounding plasma. Target molecules not excluded by the
shell freely enter the hydrogel inner meshwork to be captured
by the bait(s). The separation process takes advantage of the
enormous surface area aﬀorded by the nanoparticles. The open-
meshwork hydrogel particles are 95% occupied by the sur-
rounding solution phase and do not have the disadvantages of
boundary layers, pressuregradients,and volume requirements of
aﬃnity bead columns. Since the nanoparticles do not settle by
gravity, the plasma containing the hydrogel particles can be
separated from the cellular elements of the blood by low-speed
centrifugation (Figure 3).
’EXPERIMENTAL SECTION
Nanoparticle Synthesis and Dye Coupling. Hydrogel nano-
particles, poly(N-isopropylacrylamide-co-acrylic acid) (poly(NIPAm-
co-AAc)), were synthesized by precipitation polymerization
32 and
covalently functionalized with amino-containing dyes using amida-
tion chemistry.
33 Zero-length cross-linking amidation strategies were
performed in water or organic solvents on the basis of the hydrophilic/
hydrophobic properties of the dyes. Amine-containing hydrogel nano-
particles, poly(NIPAm-co-AA), were created by precipitation polymer-
ization and covalently functionalized with Cibacron Blue F3GA (CB)
dye by nucleophilic substitution of the amine groups in thenanoparticles
andachlorideatomintheCBdye.Anoutershellcontainingvinylsulfonicacid
(VSA) copolymerwascreatedonthedye-functionalizedparticlesbyasecond
polymerization reaction as described below.
Poly(NIPAm-co-AAc) Nanoparticle Synthesis. N-Isopropyla-
crylamide (NIPAm, Sigma-Aldrich, 4.750 g, 0.042 mol), N,N0-methy-
lenebisacrylamide(BISSigma-Aldrich,0.400g,0.0026mol),andacrylic
acid (AAc, Sigma-Aldrich, 0.525 μL, 0.0073 mol) were dissolved in
500mLofH2O,filteredusinganitrocellulosemembranediskfilter(0.45
μm pore size, Millipore), and transferred in a three-neck round-bottom
flask. The solution was purged with nitrogen for 1 h at room tempera-
ture, at medium stirring rate, and then heated to 70  C. Potassium
persulfate (KPS, Sigma-Aldrich, 0.276 g, 0.001 mol) was dissolved in
5m Lo fH 2O and was added to the solution to initiate the polymeri-
zation. The reaction was maintained at 70  C under nitrogen for 6 h.
Particles were washed five times by centrifugation (19,000 rpm, 50 min,
25  C) to eliminate the unreacted monomer and then resuspended in
600 mL of H2O.
Functionalization of Poly(NIPAm-co-AAc) Nanoparticles
with Amino Dyes in Water. Dye molecules containing an amine
group were coupled by condensation to the carboxylic group of acrylic
acid present in the poly(NIPAm-co-AAc) particles. The reaction was
conducted in a water-based solvent for the following dyes: Acid Blue 22
(AB2, Sigma), Remazol Brilliant Blue R (RBB, Sigma), Acid Black 1
(AB1, Sigma), Brilliant Blue R250 (BB, Fisher), Toluidine Blue O
(TBO, J.T. Baker), Rhodamine 123 (R12, Sigma), Disperse Yellow 3
(DY3, Fluka), and Disperse Blue 3 (DB3, Sigma). A preliminary
activation of the carboxylic group present in the nanoparticles was
performed. Briefly, 10 mL of the poly(NIPAm-co-AAc) particle suspen-
sion was centrifuged (16.1 rcf, 25 C, 15 min), the supernatant was
discarded, and the particle pellet was resuspended in 10 mL of 0.2 M
NaH2PO4pH5.Theparticlesuspension wastransferredinathree-neck
round flask, and to this were added 1 mL of 1% SDS (w/v), 824 mg of
N-(3 dimethylaminopropyl)-N0-ethyl carbodiimide hydrochloride
(EDC; Fluka Analitical), and 612 mg of solid N-hydroxy succinimide
(NHS; Sigma-Aldrich). The reaction was held at room temperature and
medium stirring rate for 15 min. Then, the suspension was centrifuged
(19,000 rpm, 50 min, 25  C), the supernatant was discarded, and the
particle pellet was resuspended in 20 mL of 0.2 M Na2HPO4 pH > 8.
After this activation step, an appropriate amount of dye (molar ratio of
dye/acrylic acid 10:1) was dissolved in 180 mL of 0.2 M Na2HPO4
buffer pH > 8, that was filtered by 0.22 μm CA filter (Corning) and
added to the activated particles; the reaction was held at room
temperature at medium stirring rate overnight. The number of acrylic
acid moles in 10 mL of particle suspension was 0.0000121. In order to
eliminate the unreacted dye, poly(NIPAm/dye) particles were washed
five times with water by centrifugation (19,000 rpm, 50 min, 25  C).
Supernatants were discarded, and particles were resuspended in 10 mL
of water.
Functionalization of Poly(NIPAm-co-AAc) Nanoparticles
with Amino-Dyes in Dimethylformamide (DMF). The amida-
tion reaction was conducted by phosponium/uranium activation in
dimethylformamide (DMF) for the following dyes: Disperse Orange 3
(DO3, Sigma), Pararosaniline Base (PR, Sigma), Disperse Yellow 9
(DY9, Sigma), Pigment Red 177 (PR1, International Laboratory
U.S.A.), and Acid Black 48 (AB4, Acros Organic). Briefly, 10 mL of
poly(NIPAm-co-AAc) nanoparticles (acrylic acid moles = 0.0000121)
was freeze-dried and resuspended in 10 mL of DMF (Sigma-Aldrich) in
a three-neck round flask. The particle suspension was purged with
nitrogen for 15 min at room temperature under medium stirring. Then,
Figure 3. One step, in solution aﬃnity capture and separation of low-
abundance target biomarkers in whole blood (plasma). Core shell
hydrogelparticlesareintroducedintotheVacutainercollectiontubeand
areallowedtoincubatewithbloodfor15min.Low-speedcentrifugation
isusedtopelletthebloodcells,whilebuoyant,open-meshworkhydrogel
particles remain in suspension in the plasma. High-speed centrifugation
isthenusedtoseparatetheparticlesfromtheplasma.Proteinsareeluted
from the nanoparticle pellet and analyzed by mass spectrometry (MS),
multiple reaction monitoring (MRM), or any other analytical platform
(e.g., immunoassay).19181 dx.doi.org/10.1021/ja207515j |J. Am. Chem. Soc. 2011, 133, 19178–19188
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68.84 mg of O-benzotriazole-N,N,N0,N0-tetramethyl-uronium-hexa-
fluorophosphate (HBTU, Peptides International), 24.52 mg of N-
hydroxybenzotriazole (HOBT, GL Biochem), and 40 μLo fN-methyl-
morpholine (Nmm; Fluka Biochemika) were added to the particle
suspension and reacted at room temperature at medium stirring rate for
5minunderanitrogenatmosphere. After5min,anappropriate amount
of dye (molar ratio of dye/AAc = 10:1) dissolved in DMF was added to
the three-neck roundflask. Thereaction was maintained under nitrogen
atmosphere for6 h.Poly(NIPAm/dye) particles were washed five times
by centrifugation (19,000 rpm, 50 min, 25  C) with decreasing concentra-
tionsofDMF(90%,75%,50%,25%,and5%) inwaterinordertoeliminate
unreacted dye and to favor particle rehydration. Supernatants were
discarded, and the particles were resuspended in 10 mL of water.
Synthesis of Poly(NIPAm-co-VSA) Nanoparticles. NIPAm
(0.475 g, 0.0042 mol), BIS (0.040 g, 0.026 mol), and vinyl sulfonic acid
(VSA; Sigma-Aldrich, 0.80.4 μL, 0.00073 mol) were dissolved in 60 mL
of H2O, filtered using a nitrocellulose membrane disk filter (0.45 μm
pore size), and transferred into a three-neck round-bottom flask. The
solution was purged with nitrogen for 1 h at room temperature, at
medium stir rate, and then heated to 70  C. KPS (0.028 g, 0.0001 mol)
wasdissolvedin2.5mLofH2Oandwasaddedtothesolutiontoinitiate
the polymerization. The reaction was maintained at 70  C under
nitrogen for 6 h. The particles were washed five times in water by
centrifugation (19,000 rpm, 50 min, 25  C) and then resuspended in
60 mL of H2O.
Poly(NIPAm/CB) Core Poly(NIPAm-co-VSA) Shell Nano-
particle Preparation. Poly(NIPAm-co-Allylamine, AA) particles
were prepared as follows. NIPAm (0.89 g, 7.83 mmol) and BIS (0.042
g,0.27mmol)weredissolvedin30mLofwaterandthenpassedthrough
a 0.2 μm nylon membrane filter. The solution was purged with nitrogen
for15minatroomtemperaturewithamediumstirringrate.AA(Sigma,
0.051 g, 0.90 mmol) was added; the solution was purged with nitrogen
for 15 min and then heated to 70  C. KPS (0.0070 g, 0.025 mmol) was
dissolvedin1.0mLofwaterandwasaddedtothesolutiontoinitiatethe
polymerization. The reaction was maintained at 70  C under nitrogen
for 3 h. The reaction was subsequently allowed to cool to room
temperature and stirred overnight. Particles were washed five times by
centrifugation (19,000 rpm, 50 min, 25  C) with water in order to
eliminate the unreacted monomer and then resuspended in 30 mL of
H2O. In order to incorporate Cibacron Blue F3GA (CB) dye, CB (0.76 g,
0.90 mmol) was dissolved in 10 mL of 0.1 M aqueous sodium car-
bonate. The poly(NIPAm-co-AA) particle suspension (10 mL volume)
was purged with nitrogen for 15 min with a medium stirring rate in a
three-neck round-bottom flask. Solid sodium carbonate (0.106 g,
1.0 mmol) was added to the suspension. The suspension was then
stirred at room temperature under nitrogen for about 1 min. The CB
solution was then added to the poly(NIPAm-co-AA) particle suspen-
sion, and the combined reaction mixture was then stirred at room
temperature under nitrogen for 48 h. The resulting poly(NIPAm/CB)
particles were harvested and washed using centrifugation (19,000 rpm,
50 min, 25  C). In order to build a VSA shell on the poly(NIPAm/CB)
core, 20 mL of poly(NIPAm/CB) particle suspension was heated at
70  C and purged with nitrogen for 1 h. NIPAm (0.156 g, 1.38 mmol),
BIS(0.013g,0.084mmol),VSA(26ul,0.334mmol),andKPS(0.092g,
0.328 mmol) were dissolved in 20 mL of water and passed through a
0.2μmnylonmembranefilter.Threemillilitersofthissolutionwasaddedto
the poly(NIPAm/CB) particle suspension, and the remaining 17 mL of
solution was added in aliquots of 3 mL every 5 min. Poly(NIPAm/CB)
core poly(NIPAm-co-VSA) shell particles were washed five times in
water by centrifugation (19,000 rpm, 50 min, 25  C).
Nanoparticle Characterization. The temperature dependence
of particle size was determined via photon correlation spectroscopy
(Submicrometer Particle Size Analyzer, Beckman Coulter). The measure-
mentofparticlediameterwasperformedusingwaterasadiluent(refractive
index (RI) = 1.333, diluent viscosity = 0.890 cP). The test angle was 90 .
A v e r a g ev a l u e sw e r ec a l c u l a t e df o rthree measurements using a 200 s
integrationtime,and thesolutionswereallowedtothermallyequilibratefor
10 min before each set of measurements. Measured values were then
converted to particle sizes via the Stokes Einstein relationship.
34 The
particles were further characterized by atomic force microscopy (AFM)
using an NSCRIPTOR DPN System (NanoInk). Particles in suspension
(1μg/mL) were deposited on freshly cleaved mica in a humid atmosphere
for 15 min and dried under nitrogen before measurement. Images were acquired
underACmodeusingasilicontipwithatypicalresonancefrequencyof300kHzand
a radius smaller than 10 nm. Incorporation of dye in the particles was assessed by
weighing the dry particles before and after dye coupling.
Nanoparticle Incubation with Serum, Plasma, Blood, and
Protein Solutions. Aliquots of 500 μL of serum and EDTA plasma
were diluted 1:2 with 50 mM TrisHCl pH 7, mixed with 500 μLo f
hydrogel particles functionalized with the molecular baits described
above, and incubated for 15 min at room temperature. Particles were
separated by centrifugation (16.1 rcf, 25  C, 10 min) and washed with
buffers specific for the molecular baits listed in Table 1. The particle
pellet was incubated for 15 min at room temperature with 600 μLo f
elution buffer specific for the molecular baits listed in Table 1 and then
centrifuged (16.1 rcf, 25  C, 10 min). The elution step was repeated
twice,andtheeluateswerecombinedinthesamevialandthendriedina
vacuum concentrator.
Blood was collected in EDTA-containing blood collection tubes
(Vacutainer EDTA Tubes, Becton Dickinson). Aliquots of 1 mL of
blood were diluted 1:2 with physiologic solution (0.9% NaCl). One
milliliter of hydrogel particle suspension was added to the blood and
incubated for 15 min. In order to separate the blood cells, the blood
 particle mixture was centrifuged (200 rcf, 25  C, 10 min), and the
plasma supernatant was saved. The plasma was then centrifuged at
higher speed (16.1 rcf, 25  C, 10 min), the supernatant was discarded,
and the particle pellet was washed and eluted as previously described,
using appropriate buﬀers for each type of particle (Table 1).
Proteins (human growth hormone (Lilly), hepatocyte growth factor
(Antigenix America Inc.), ﬁbroblast growth factor 22 (Cell Sciences),
vascular endothelial growth factor (Cell Signaling Technologies), eotaxin
2 (AbD Serotec), IGF binding protein 7 (IGFBP7) (Preprotech),
interleukin-6 (AbD Serotech), chemokine (C C motif) ligand 22
(CCL22) (R&D Systems), survivin (Novus Biologicals), B-cell lym-
phoma 2 (bcl-2) (Fisher Scientiﬁc), osteopontin (Novus Biologicals),
troponin-I (AbD Serotec), and kallikrein-6 (ARP American Research
Products)) were each dissolved in 25 μL of 50 mM TrisHCl pH 7 at a
concentration of 0.05 μg/μL, mixed with 25 μL of particle suspension,
and incubated for 15 min at room temperature. Particles were separated
by centrifugation (16.1 rcf, 25  C, 10 min), washed with water (16.1 rcf,
25  C, 10 min), and analyzed by SDS PAGE.
Interleukin-8 (IL8) was dissolved in synthetic sweat (Corkig) at a
concentration of0.05μg/μL,andthepHofthesolutionwasadjustedto
8with1MNaOH.Trypsin(Promega)wasaddedtotheIL8solutionata
100:1 protein to protease w/w ratio. Poly(NIPAm/DY9) particles were
added to the IL8, trypsin-containing solution and the mixture left to
incubate for 3 h at 37  C.
Aliquots of 100 μL of poly(NIPAm-co-VSA) particles were mix-
ed with 2 μg of trypsin-digested human serum albumin (Michrom
Bioresources)andallowedtoincubatefor30min.Particleswerewashed
andelutedwiththebuﬀersindicatedinTable1.Theeluatewasdriedina
SpeedVac and injected into an LTQ-Orbitrap mass spectrometer
(ThermoFisher). Isoelectric points and molecular weights of trypsin-
generated peptides derived from albumin were calculated online at
http://isoelectric.ovh.org/.
Immunoassay Measurement of Troponin-I. Poly(NIPAm/
DB3) and poly(NIPAm/RBB) particles were mixed with a solution of
troponin-I (in 50 mM Tris HCl pH 7), incubated for 15 min at room19182 dx.doi.org/10.1021/ja207515j |J. Am. Chem. Soc. 2011, 133, 19178–19188
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temperature and then were separated by centrifugation (16.1 rcf, 25  C,
10 min). The concentration of troponin-I was measured using the
Immulite 1000 Troponin-I System (Siemens Healthcare Diagnostics).
Particle eluates were lyophilized overnight, reconstituted in Immulite
Sample Diluent (Siemens Healthcare Diagnostics), and assayed accord-
ing to the manufacturer’s instructions.
Dissociation Constant Calculation. The dissociation constant
between the particles and troponin-I was estimated by solving the ordinary
differential equations derived from the dissociation equilibrium reaction of
bound versus free analyte using the R software, deSolve package.
35
LC MS/MS analysis. Eluates from the particles were analyzed by
mass spectrometry. Proteins were dried in a SpeedVac and were
reconstituted in 8 M urea, reduced by 10 mM DTT, alkylated by
50 mM iodoacetamide, and digested by trypsin (Promega) at 37  C
overnight.TrypticpeptideswerefurtherpurifiedbyZip-Tip(Millipore)
and analyzed by reversed-phase liquid chromatography nanospray
tandem mass spectrometry (LC MS/MS) using an LTQ-Orbitrap
mass spectrometer (ThermoFisher). After sample injection by auto-
sampler, the C18 column (0.2 mm   50 mm, Michrom Bioresources,
Inc.)was washedfor2minwithmobile phaseA(0.1% formicacid), and
peptides were eluted usingalineargradient of0% mobilephase B(0.1%
formic acid, 80% acetonitrile) to 50% mobile phase B in 90 min at
500nL/min,thento100%mobilephaseBforanadditional5min.TheLTQ
mass spectrometer was operated in a data-dependent mode in which
eachfullMSscanwasfollowedbyfiveMS/MSscanswherethefivemost
abundant molecular ions were dynamically selected for collision-
induced dissociation (CID) using a normalized collision energy of 35%.
Tandem mass spectra were searched against the NCBI human database
with SEQUEST using tryptic cleavage constraints. High-confidence
peptide identifications were obtained by applying the following filter
criteriatothesearchresults:Xcorrversuschargeg1.9,2.2,3.5for1
+,2
+,
3
+ ions; ΔCn > 0.1; probability of randomized identification e0.01.
MultipleReactionMonitoring(MRM)Analysis.Humanurine
wascentrifuged(10min,1000rpm,4 C)inordertoremovethecellular
debris, and the specific gravity was recorded. Human growth hormone
(hGH) was spiked in human urine at a concentration of 50 ng/mL.
Aliquots of 1 mL of urine containing hGH were incubated with 500 μL
of Remazol Brilliant Blue R particles for 30 min at room temperature.
The particles were separated by centrifugation (16.1 rcf, 10 min, 25  C)
and washed with water (16.1 rcf, 10 min, 25  C). Proteins captured by
theparticleswereelutedwith500μLofelutionbuffer(70%acetonitrile,
10% ammonium hydroxide) and dried in a vacuum concentrator. Fifty
microliters ofurine solution and particle eluate were prepared forMRM
analyses by: (1) reduction with 10 mM dithiothreitol in 1 M urea/
50 mM ammonium bicarbonate (NH4HCO3) at room temperate for
60 min, (2) alkylation with 50 mM iodoacetamide at room temperature
in the dark for 20 min, (3) overnight enzymatic digestion with 0.5 μgo f
sequencing grade trypsin in 50 mM ammonium bicarbonate, pH 8 at
37  C. Digestions were quenched with the addition of 2 μLo f
concentrated trifluoroacetic acid and then dried in a vacuum concen-
trator. Samples were then reconstituted with 50 μL of 200 μg/mL
glucagon (Sigma-Aldrich, St. Louis, MO) in 0.1% formic acid. Sample
digests were analyzed with a TSQ Quantum Ultra Triple Quadrupole
mass spectrometer (ThermoFisher Scientific). Samples were loaded
onto a 1 mm   150 mm Hypersil Gold 3 μm particle C-18 reversed
phase column (Thermofisher Scientific) with an Accela autosampler
(Thermofisher Scientific) fitted with a 10 μL sample loop. The LC
pumpwasanAccela(ThermoFisherScientific)operatedat160μL/min,
and effluent was directed into the mass spectrometer using an IonMax
source. After sample injection, the column was washed for 5 min with
98% mobile phase A (0.1% formic acid), and peptides were eluted using
alineargradient of2%mobilephase B(0.1%formic acidinacetonitrile)
to 50% mobile phase B in 20 min. The instrument divert valve was
switched to waste before and after the peptides eluted in order to keep
the source free of excess salts and debris. Both Q1 and Q3 resolution
were set to 0.7 fwhm. Q2 contained 1.5 mTorr of argon.
The scan width was 0.002 m/z, and dwell time was 15 ms. Collision
energies (CE) were calculated according to the formula: 0.034  
precursor ion mass m/z + 3.314. Each sample was analyzed in triplicate.
Peptide FPTIPLSR (465.77
2+) from hGH, with transitions 392.24,
472.29, 585.37, 686.42, and 783.47 were chosen for MRM analyses
on the basis of previous work with tryptic digests of hGH standards.
MRM results were loaded into the Pinpoint program, version 1.0
(ThermoFisher Scientiﬁc) for data analysis. Data were divided into
twogroups:(1)nanoparticle-enrichedurinesample(triplicateanalyses)
and (2) non-nanoparticle urine sample (triplicate analyses). Peak width
tolerance was 30 s, the alignment error tolerance was 0.5 min, and
the minimum signal threshold was 100. The fragment ion peak areas for
all transitions were summed and the average areas calculated using
the triplicate analyses for the nanoparticle and non-nanoparticle
samples.
Table 1. Washing and Elution Buﬀers for Each Kind of
Nanoparticle
chemical bait
in the particles
washing
buﬀer
elution
buﬀer
Cibacron Blue F3GA,
Remazol Brilliant Blue R
0.25 M
NaSCN
Twice
70% acetonitrile,
10% ammonium
hydroxide
Disperse Yellow 9,
Disperse Yellow 3,
Disperse Orange 3,
Pararosaniline base,
Pigment Red 177,
acid black 48, Acid blue 22,
Acid black 1; Brilliant Blue R250,
Toluidine Blue,
Rhodamine 123,
Disperse Blue 3, VSA, AAc
0.5   PBS
and 0.5  
PBS/20%
acetonitrile
1% triﬂuoroacetic
acid,
80% acetonitrile
Figure 4. Light-scattering analysis of particles functionalized with
diﬀerent chemical baits. Hydrodynamic diameter (DH) decreased with
increasesinthetemperatureofthesolution.Thetemperature diameter
relationship is inﬂuenced by the type of dye incorporated.19183 dx.doi.org/10.1021/ja207515j |J. Am. Chem. Soc. 2011, 133, 19178–19188
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’RESULTS AND DISCUSSION
We identiﬁed a series of small novel organic dye molecules
possessing extremely high protein-binding aﬃnity (KD <1 0
 11
M, Figure 2). These dyes act as molecular baits by binding
proteins and peptides, likely through a combination of hydro-
phobic and electrostatic forces, by inserting their aromatic rings
into hydrophobic pockets present on the protein surfaces.
30
Weimmobilizedthebaitsbybindingaminogroupsinthedyes
to carboxylic groups in the particles (Figure 4 shows the changes
in the hydrodynamic volume after dye functionalization). Zero-
length cross-linking amidation strategies were used and opti-
mized on the basis of hydrophilic/hydrophobic dye properties.
33
As shown in Figure 5 when hydrogel nanoparticles containing
one of 17 diﬀerent classes of organic chemistries were screened
against a panel of 13 known low-abundance diagnostically
relevant biomarker proteins, strong bait selectivity for speciﬁc
proteins or classes of proteins was noted. For example, hepato-
cyte growth factor (HGF) was captured by poly(NIPAm/DY3)
particles and excluded by poly(NIPAm/DB3) particles (see also
Figures 6 and 7).
We determined that the aﬃnity of dye protein binding
reactions was dependent on the type of reactive group substitu-
tion (Figure 8A). Troponin-I, a biological marker for cardiac
muscletissueinjury,ispresentinthebloodatlowconcentrations
(5 pg/mL),
47 below the detection limit of routine mass spectro-
metry. Remazol brilliant blue R (RBB)-functionalized particles
sequestered more than 99.9% of troponin-I present in solution
(estimated dissociation constant KD < 1.1   10
 11 M) so that
the troponin-I concentration in the supernatant outside the
particle at equilibrium (<10 min) was reduced below the detec-
tion limit (50 pg/mL) of the Immulite clinical immunoassay.
Modiﬁcationinthechemicalgroupsubstitution(keepingthebait
moleculesequimolar)reducedthecapture eﬃciencyduetoa10-
fold reduction in the KD (2.4   10
 10 M, Figure 8A).
The advantage of such high-aﬃnity binding dye chemistries is
severalfold:(a) highON/OFFrateratio(estimated9.2 10
10M
 1
for poly(NIPAm/RBB) nanoparticles and 4.2   10
9 M
 1 for
poly(NIPAm/DB3)) nanoparticles achieves rapid complete
Figure5. Nanoparticlesfunctionalizedwith17diﬀerentmolecularbaits
(poly(NIPAm/ABB), poly(NIPAm/DB3), poly(NIPAm/RBB), poly-
(NIPAm/PR1), poly(NIPAm/AB4), poly(NIPAm-co-VSA), poly(NIPAm/
DY3), poly(NIPAm/AB1), poly(NIPAm/DO3), poly(NIPAm/DY9),
poly(NIPAm/R12), poly(NIPAm/TBO), poly(NIPAm-co-AAc), poly-
(NIPAm/PR), poly(NIPAm/BB), poly(NIPAm/AB2), poly(NIPAm/
CB)) show preferential high aﬃnities for 13 speciﬁc low-abundance
protein analytes as indicated by the color of the cell. The expected
concentrations of the indicated proteins in serum/plasma were derived
from the literature.
36 48.
Figure 6. Heat map representation of serum proteins captured by
nanoparticles functionalized with diﬀerent molecular baits (poly(NIPAm/-
RBB), poly(NIPAm/CB), poly(NIPAm-co-VSA), poly(NIPAm/DY9),
poly(NIPAm/DO3),poly(NIPAm/DY3),poly(NIPAm/PR1),poly-
(NIPAm/AB4), poly(NIPAm/BB), poly(NIPAm-co-AAc), poly(NIPAm/
AB1),poly(NIPAm/ABB).Dyesincorporatedintheparticlesareshown
ontheXaxis,proteinsidentiﬁedwithMSanalysisofserumpreprocessed
withtheparticlesareshownintheYaxis.Eachdyebaitisrepresentedby
adi ﬀerentcolor.Examplelow-abundanceproteinsuniquelycaptured by
speciﬁc dye baits are highlighted.
Figure 7. Poly(NIPAm/DY9) and poly(NIPAm/DO3) particles cap-
ture unique groups of proteins from serum. Addition of two types of
hydrogelparticlescomplementeachotherbycombiningtheirrespective
protein repertoire. Example low-abundance proteins are highlighted in
the boxes.19184 dx.doi.org/10.1021/ja207515j |J. Am. Chem. Soc. 2011, 133, 19178–19188
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capture of all low-abundance ligands, (b) high-aﬃnity binding
can protect captured proteins from degradation
19 (Figure 8B),
and (c) targeted low-molecular weight proteins bound to abun-
dant carrier proteins in biological ﬂuid can be competed away by
thehigh-aﬃnitybaitandstrippedawayfromthecarrierprotein.
19
AsshowninFigure9,whenpoly(NIPAm/RBB)nanoparticles
areintroducedintoa1mLsamplecontaining50ng/mLofhGH,
all of the hGH (50 ng) is sequestered in the nanoparticles in one
step and can be eluted in 50 μL, yielding a 20-fold increase in
analyte concentration to meet the MRM limits of sensitivity. A
larger starting sample volume will yield a proportionally higher
increase in analyte concentration.
Our results suggest that particles containing organic struc-
tures, such as vinyl sulfonic acid (VSA), excluded (1) full-length
albumin by size sieving and (2) peptides derived from albumin
that are below the size cutoﬀ of the eﬀective pore size of the
particlebyselectiverepulsion.VSA-containingparticlesexcluded
albumin but still retained aﬃnity for wide classes of other
proteins and peptides. These ﬁndings are consistent with pre-
vious literature in which VSA-containing polymers were selec-
tively able to prevent albumin absorption
49 but retained the
ability to form complexes with proteins such as trypsin.
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Poly(NIPAm-co-VSA) particles completely excluded full-
length bovine serum albumin (BSA) while sequestering inter-
leukin-6 from solution (Figure 10A). In a separate experiment,
fragment peptides derived from trypsinization of albumin were
incubated with poly(NIPAm-co-VSA) particles. Albumin-de-
rived peptides below the size exclusion cutoﬀ for the poly(NIP-
Am-co-VSA) particles (Figure 5) were consistently excluded by
the poly(NIPAm-co-VSA) particles at a variety of pH values
(Table 2). These same particles that excluded low-molecular
weightalbuminfragmentscontinuedtosequesterabroadvariety
Figure 8. (A) Bait chemical structure determines aﬃnity and can
capture or exclude select proteins. Poly(NIPAm/DB3) and poly-
(NIPAm/RBB) nanoparticles were incubated with troponin-I. DB3
and RBB are anthraquinone rings that diﬀer in their side groups. RBB
depleted greater than 99.9% (estimated dissociation constant KD <
10
 11 M) while DB3 depleted 83% (KD =1 0
 10 M), at equilibrium
(<10 min). (B) Proteins sequestered in the nanoparticles are protected from
enzymaticdegradation.Interleukin-8(IL8)dilutedinartiﬁcialsweatwas
incubated with excess trypsin at 37  C in the presence or absence of
poly(NIPAm/DY9) particles. SDS PAGE analysis revealed that in the
absence of poly(NIPAm/DY9) particles, the IL8 band disappeared, and
a fainter band at lower molecular weight appeared, indicating the
presence of a degradation product (lane 2). In the presence of poly-
(NIPAm/DY9)particles,IL8isfullyprotectedfromtrypsindegradation
(lane 5). Incubation of IL8 with sweat alone at 37  C caused the intact
IL8 band to disappear (lane 3), while poly(NIPAm/DY9) particles
yieldedafulldensity bandfortheintactprotein(lane4),suggestingthat
IL8 was protected from degradation at 37  C by the nanoparticles.
Figure 9. Poly(NIPAm/RB) particles eﬀectively increase the detection
sensitivity for MRM analysis of human growth hormone (hGH) spiked
in human urine.
Figure10. (A)Poly(NIPAm-co-VSA)particlesexcludedalbuminwhile
capturing interleukin 6 (IL6). SDS PAGE analysis shows that all the
albuminisleftinthesupernatant(lane2)whilealltheIL6iscapturedby
the particles (lane 3). For comparison purposes, poly(NIPAm/CB)
nonshelledparticlesareshown.InthiscaseallIL6wascaptured(lane4),
but albumin was also detectable in the particles (lane 5) because CB
bindstoalbuminspecies.(B)Theadditionofavinylsulfonicacid(VSA)-
functionalized shell to cibacron blue F3GA (CB)-containing particles
decreased the number of unwanted albumin peptide hits (upper) while
at the same time increased the frequency of MS hits for target proteins
(e.g., Apo-CI) (lower) (Supporting Information Table 4). (C) Poly-
(NIPAm/CB) core (NIPAm-co-VSA) shell particles greatly enhance
thelow-molecularweightproteinconcentrationinwholeblood(lane3)
while fully excluding high-molecular weight abundant proteins such as
albumin and immunoglobulins.19185 dx.doi.org/10.1021/ja207515j |J. Am. Chem. Soc. 2011, 133, 19178–19188
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of non-albumin peptides below the size exclusion cutoﬀ of the
poly(NIPAm-co-VSA) particles (Figure 5 and Supporting In-
formation Table 1). The mechanism by which poly(NIPAm-co-
VSA) particles repel albumin-derived peptides is not completely
known and cannot be explained by simple charge eﬀects. In fact,
albumin peptides below their calculated isoelectric point at pH 8
(therefore carrying net positive charges) did not bind to the
highly ionized sulfonate groups. Excluded peptides derived from
albumin may not display the correct pattern of hydrophobic
residues and charge distribution that matches the VSA-function-
alized nanoparticle landscape. Exclusion of classes of peptides by
speciﬁc bait chemistries is a new principle in peptide separation.
In order to maximize the performance of the particles, we
added a shell containing VSA to poly(NIPAm/CB) core parti-
cles. CB is known to bind albumin and albumin peptides (along
with a broad number of other proteins) with high aﬃnity.
We performed MS analysis of poly(NIPAm/CB) core poly-
(NIPAm-co-VSA) shell particle puriﬁed plasma. Albumin pep-
tide hits present in the particle eluate dramatically decreased if
theCBbaitinthecorewasseparatedfromtheplasmabytheVSA
shell (Figure 10B). Since the molecular weight cutoﬀ of the
particles is 30 kDa (Figure 10C) and albumin fragments are
normallypresentintheblood,
20albuminspeciesexcludedbythe
particles are not only full-length molecules but also albumin
fragments below 30 kDa.
Thus, in one step, undesired albumin species are excluded.
TheadditionoftheVSAshelldidnothinderthecapture ofother
target analytes (e.g., Apo CI, Figure 10B). Poly(NIPAm/CB)
core poly(NIPAm-co-VSA) shell particles allowed for the se-
quencing of low-abundance, low-molecular weight plasma pro-
teins(Table3)thatwerenotidentiﬁedwithoutthedualfunction
nanoparticles. An example of 200 proteins that were captured by
poly(NIPAm/CB) core poly(NIPAm-co-VSA) shell particles
is shown in Supporting Information Table 3. Since the molec-
ular weight cutoﬀ of poly(NIPAm/CB) core poly(NIPAm-co-
VSA) shell particles is 30 kDa we can state that 65% of captured
proteins was represented in serum as fragments of the parent
molecule.
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We investigated the power and extent of protein and peptide
enrichmentforlow-molecularweight,low-abundanceproteinsin
a pool of healthy donor sera or plasma. We compared the
peptides identiﬁed by LC MS/MS with and without a one-step
processing through poly(NIPAm/CB) core poly(NIPAm-co-
VSA) shell particles.
A large number of diagnostic low-molecular weight proteins
andpeptideswhoseconcentrationinbloodislessthan10ng/mL
were identiﬁed by MS after poly(NIPAm/CB) core poly-
(NIPAm-co-VSA) shell nanoparticle harvesting. Moreover, an
additional set of peptides belonging to low-abundance proteins
were identiﬁed that were not previously found by MS analysis
in whole blood, serum, or EDTA plasma, nor included in the
PeptideAtlas database, the most comprehensive high conﬁdence
collection of MS identiﬁed proteins
52,53 (Supporting Informa-
tion Figures 1 and 2 and Tables 1 and 2). Compared to the
samples processed without nanoparticle harvesting, the ability of
the nanoparticles to concentrate the low-abundance pepti-
dome from whole blood was evident by SDS PAGE analysis
(Figure 10C).
Proteins whose molecular weight was lower than 30 kDa were
captured by the particles. Thus, the nanoparticle technology
described herein can be used for biomarker discovery in whole
blood as a single preprocessing step. The nanoparticles will
remain in the plasma following low-speed centrifugation to
remove the cellular content (Figure 3). In the future it will be
important to evaluate the eﬀect of potential interfering sub-
stances present in whole blood and plasma such as lipemia,
bilirubinemia, and hemolysis.
Harvestinghydrogelnanoparticlespossessimportantfeatures,
aswehavedemonstratedinpreviousstudiesusingpoly(NIPAm-
co-AAc) and poly(NIPAm/CB): (a) use of the nanoparticles
ampliﬁes the eﬀective sensitivity (by concentrating the sample
analyte into a smaller volume and excluding unwanted contam-
inants) while maintaining the linearity of quantitative im-
munoassays;
16 (b) nanoparticle preprocessing generated high
yields and high precision when applied to clinical grade bio-
marker studies;
17 (c) if a quantitative immunoassay is previously
established,nanoparticlepreprocessingishighlysuitableforveriﬁca-
tion and validation of MS-identiﬁed candidate biomarkers.
18
The new type of hydrogel core shell nanoparticles (poly-
(NIPAm/CB) core poly(NIPAm-co-VSA) shell particles) de-
scribed herein achieved a 10,000 fold eﬀective ampliﬁcation of
the low-abundance, low-molecular weight proteins and peptides
that could be identiﬁed by MS as demonstrated by examples of
morethan200low-abundanceproteins(SupportingInformation
Table 3; Figure 11). The result was the identiﬁcation of a large
series of novel candidate proteins not previously identiﬁed with
mass spectrometry analysis in human serum (Table 3, Support-
ing Information Tables 1 and 2 and Figure 1). While these
candidate protein spectra have been manually validated (Support-
ing Information Figure 2) and high stringency MS cutoﬀﬁ lters
have been applied (Experimental Section), a limitation of the
current study is that completely new antibodies and quantitative
immunoassays will have to be developed to independently verify
these proteins by immunochemical methods in serum.
Table 2. Example Peptides Derived from Human Serum
Albumin That Were Excluded by Poly(NIPAm-co-VSA) Par-
ticles at Diﬀerent pH Values
a
peptide hits (P/S)
peptide pI MW pH 8 pH 4 pH 2
K.AEFAEVSK.L 6.5 1121.3 0/0 0/0 0/1
K.AVM*DDFAAFVEK.C 4.4 1653.8 0/22 6/30 0/0
K.AVMDDFAAFVEK.C 4.4 1573.8 0/51 8/48 0/0
K.DLGEENFK.A 4.4 1150.2 0/0 0/3 0/2
K.FQNALLVR.Y 10.4 1251.4 0/71 22/105 18/68
K.KLVAASQAALGL.- 10.8 1269.5 0/18 0/0 1/12
K.KQTALVELVK.H 10.5 1393.6 0/31 6/15 4/14
K.KYLYEIAR.R 10.4 1339.6 0/26 0/4 1/9
K.LDELRDEGK.A 4.5 1273.4 0/1 0/14 0/10
K.LVAASQAALGL.- 9.7 1141.3 0/76 12/120 10/66
K.PLVEEPQNLIK.Q 6.5 1535.8 0/4 0/3 0/1
K.SLHTLFGDK.L 9.5 1258.4 0/6 0/5 0/0
K.VPQVSTPTLVEVSR.N 9.7 1754.0 0/42 7/11 6/13
K.YLYEIAR.R 10.0 1211.4 0/1 15/11 11/32
R.FKDLGEENFK.A 6.6 1453.6 0/126 10/26 20/22
R.HPDYSVVLLLR.L 9.3 1580.6 0/0 2/1 0/2
R.RPCFSALEVDETYVPK.E 4.6 2139.4 0/0 0/2 0/0
aAlbuminwastrypsindigestedbeforeparticleincubation.Poly(NIPAm-
co-VSA) particles excluded all albumin tryptic peptides at pH 8. P =
particle content, S = supernatant.19186 dx.doi.org/10.1021/ja207515j |J. Am. Chem. Soc. 2011, 133, 19178–19188
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’CONCLUSIONS
High buoyancy, polymer open-meshwork, core shell hydro-
gel nanoparticles covalently functionalized with combinations of
novelorganicdyebaitsoﬀeraone-steptechnologyforbiomarker
harvesting, concentration, and stabilization, with simultaneous
exclusion of unwanted abundant molecules. The nanoparticles
exhibit three physicochemical properties: (1) speciﬁc novel dye
chemistriesimmobilizedintheparticlecorepossessextremely
high aﬃnity for select classes of proteins and peptides; (2) a
chemicalspeciespresentintheshell,VSA,selectivelyexcludes
fragments and peptides derived from albumin, and (3) the outer
shelloftheparticleperformsphysicalsizesieving,excludinglarge
unwanted abundant molecules such as immunoglobulins. Dual-
function hydrogel nanoparticles can dramatically magnify small
protein and peptide identiﬁcation and measurement from
complex biological solutions, using any current or future an-
alytical platform, while stabilizing the analytes against degrada-
tion. The ﬂuid samples used in the present sample were blood,
urine, and sweat. The technology is applicable to any biologic
solution-phase sample. We are currently incorporating nano-
particles into a skin patch that continuously harvests, concen-
trates, and preserves analytes present in the skin transudate
for proteomic analysis. Bait-loaded core shell nanoparticles
are being used for biomarker discovery in lymph, saliva, and
cerebrospinal ﬂuid.
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Figure 11. Poly(NIPAm/CB) core poly(NIPAm-co-VSA) shell na-
noparticles increase the sensitivity of LC MS/MS analysis by 4 orders
of magnitude as demonstrated by examples of more than 200 low-
abundance proteins speciﬁed in Supporting Information Table 3.
Conventional MS/MS analysis (90 min linear gradient at 500 nL/
min,data-dependentmode,Xcorrversuschargeg1.9,2.2,3.5for1
+,2
+,
3
+ions;ΔCn>0.1;probabilityofrandomizedidentiﬁcatione0.01)was
used to compare the same serum set before and after nanoparticle
processing. The ultimate sensitivity of the analysis depends on the
starting sensitivity of the system.
Table 3. Example Candidate Proteins Identiﬁed by LC MS/MS LTQ Orbitrap Analysis for Samples Preprocessed with
Poly(NIPAm/CB) Core Poly(NIPAm-co-VSA) Shell Nanoparticles That Were Not Present in Samples Preprocessed with
Poly(NIPAm/CB) Unshelled Nanoparticles or Poly(NIPAm-co-VSA) Unshelled Particles
a
accession protein blood concentration [pg/mL] and ref
38455402 lipocalin 2 (oncogene 24p3) [Homo sapiens]5 0
54
27765091 ST6 β-galactosamide α-2,6-sialyltranferase 1 isoform a [Homo sapiens] 15,000
55
148664205 endothelial cell adhesion molecule [Homo sapiens] 30,000
56
4759074 small inducible cytokine A16 precursor [Homo sapiens] 30,000
57
4502101 annexin I [Homo sapiens] 50,000
58
163659899 insulin-like growth factor 1 (somatomedin C) 100,000
59
11321593 insulin-like growth factor binding protein 6 150,000
59
62243290 insulin-like growth factor binding protein 4 400,000
60
10834982 insulin-like growth factor binding protein 5 400,000
60,61
144953895 nidogen 2 precursor [Homo sapiens] 12,000,000
61
49574514 matrix Gla protein [Homo sapiens] 90,000,000
62
33186925 AMP-activated protein kinase γ-2 subunit isoform a [Homo sapiens U
157168362 nucleoside phosphorylase [Homo sapiens]U
4507475 transglutaminase 1 [Homo sapiens] U
4502693 CD9 molecule [Homo sapiens] U
48375180 CD36 antigen [Homo sapiens] U
9257257 WD repeat domain 1 [Homo sapiens]U
222080092 WD repeat domain 91 [Homo sapiens]U
40254462 guanine nucleotide binding protein (G protein), q polypeptide [Homo sapiens]U
aU = unknown. The presence of the VSA shell greatly increases the number and dynamic range of proteins sequestered for discovery.19187 dx.doi.org/10.1021/ja207515j |J. Am. Chem. Soc. 2011, 133, 19178–19188
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